EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

No value of non‐selective beta‐blockers after TIPS ‐insertion

Anja Tiede iD, Lena Stockhoff, Hannah Rieland, Zhaoli Liu, Jim B Mauz, Tammo L Tergast iD, Martin A Kabelitz, Sarah S Schütte, Alena F Ehrenbauer, Bernhard C Meyer, Heiner Wedemeyer iD, Jan B Hinrichs und 4 weitere

Alimentary Pharmacology & Therapeutics · 2024

DOI: 10.1111/apt.18204 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2024. Verfasst von Anja Tiede und 15 weiteren Autor:innen. Beteiligte Einrichtung: Hannover Medical School, Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover, Germany. Hauptthemen laut MEDLINE: Portasystemic Shunt, Transjugular Intrahepatic, Adrenergic beta-Antagonists, Hypertension, Portal, Liver Cirrhosis. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Else Kröner-Fresenius-Stiftung, Förderstiftung MHH plus.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims Non‐selective beta‐blockers (NSBB) are a well‐established treatment in patients with clinically significant portal hypertension. However, their potential role after insertion of a transjugular intrahepatic portosystemic shunt (TIPS) still needs to be determined. Of note, recent studies suggested that favourable anti‐inflammatory effects of NSBB might be independent from pressure reduction. This study aimed to evaluate whether NSBB‐treatment is associated with amelioration of systemic inflammation (SI), hepatic decompensation and survival after TIPS‐insertion.

Methods

In a retrospective study comprising 305 consecutive patients, we investigated the impact of NSBB‐intake at TIPS‐placement on periinterventional cirrhosis‐associated complications and continued NSBB‐treatment after discharge on complications including hepatic decompensation and mortality during 1‐year follow‐up, employing multivariable competing‐risk‐analyses. In a prospective cohort including 45 patients, we performed a comprehensive analysis of SI analysing 48 soluble inflammatory markers (SIMs) at baseline plus 3 and 6 months after TIPS‐insertion.

Results

Overall, 175 (57.4%) patients received NSBB‐therapy prior to TIPS‐insertion; upon discharge, this decreased to 131 (22.9%), with 36 (27.5%) discontinuing NSBB within 1‐year follow‐up. Neither NSBB‐therapy at TIPS‐insertion nor treatment‐continuation after discharge were associated with lower risks for hepatic decompensation, individual cirrhosis‐associated complications or mortality neither in the periinterventional period nor during follow‐up. Similarly, in the prospective cohort NSBB‐intake was not linked to lower levels or a more prominent change of WBC, CRP or any other SIM at any of the investigated time points.

Conclusion

NSBB‐therapy at the time of TIPS‐insertion and its (dis‐)continuation afterwards seems to have no significant impact on SI, development of hepatic decompensation and survival.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Portasystemic Shunt, Transjugular IntrahepaticAdrenergic beta-AntagonistsHypertension, PortalLiver CirrhosisHumansFemaleMaleMiddle AgedRetrospective StudiesAgedProspective StudiesTreatment OutcomeInflammationAdult

Substanzen

Adrenergic beta-Antagonists

Autor:innen und Institutionen

  • Hannover Medical School, Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover, Germany.
  • German Center for Infection Research (DZIF), Hannover-Braunschweig, Hannover, Germany.
  • Center for Individualized Infection Medicine (CIIM), c/o CRC Hannover, Hannover, Germany.
  • TWINCORE, Centre for Experimental and Clinical Infection Research, a joint venture between the Helmholtz-Centre for Infection Research (HZI) and the Hannover Medical School (MHH), Hannover, Germany.
  • Department of Diagnostic and Interventional Radiology, Hannover Medical School, Hannover, Germany.
  • St. Bernward Hospital, Radiology, Hildesheim, Germany.

ORCID-Profile: Anja Tiede, Tammo L Tergast, Heiner Wedemeyer, Markus Cornberg, Benjamin Maasoumy

Förderung

  • Else Kröner-Fresenius-Stiftung
  • Förderstiftung MHH plus

Zitieren

APA

Tiede, A., Stockhoff, L., Rieland, H., Liu, Z., Mauz, J. B., Tergast, T. L., Kabelitz, M. A., Schütte, S. S., Ehrenbauer, A. F., Meyer, B. C., Wedemeyer, H., Hinrichs, J. B., Cornberg, M., Falk, C. S., Xu, C. J., & Maasoumy, B. (2024). No value of non‐selective beta‐blockers after TIPS ‐insertion. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.18204

Vancouver

Tiede A, Stockhoff L, Rieland H, Liu Z, Mauz JB, Tergast TL, et al. No value of non‐selective beta‐blockers after TIPS ‐insertion. Alimentary Pharmacology & Therapeutics. 2024. doi:10.1111/apt.18204

BibTeX
@article{Tiede2024,
  author = {Tiede, Anja and Stockhoff, Lena and Rieland, Hannah and Liu, Zhaoli and Mauz, Jim B and Tergast, Tammo L and Kabelitz, Martin A and Schütte, Sarah S and Ehrenbauer, Alena F and Meyer, Bernhard C and Wedemeyer, Heiner and Hinrichs, Jan B and Cornberg, Markus and Falk, Christine S and Xu, Cheng-Jian and Maasoumy, Benjamin},
  title = {No value of non‐selective beta‐blockers after TIPS ‐insertion},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2024},
  doi = {10.1111/apt.18204}
}
Kostenlos starten →